Pipeline dossier

NIH & clinical-trial pipeline signals for ASTRAZENECA PLC (AZN)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for AZN, mapped to public ticker AZN (CIK 0000901832). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingAZN55% conf

ASTRAZENECA PLC (AZN) — PHASE2 primary completion in ~140 days

Upstream (observed)
Clinical trial status (PHASE2) — A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 4 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 6 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingAZN35% conf

ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 4 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

JSON API for this entity →